Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data
Arthritis & Rheumatology · 2025-07 · 77 (7) · 876-883
DOI: 10.1002/art.43096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 27.01.2025. Verfasst von Yann Nguyen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin-Bicêtre, Hôpital Beaujon, Assistance Publique - Hôpitau…. Hauptthemen laut MEDLINE: Sjogren's Syndrome. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: French Ministry of Health grant (Programme Hospitalier de Recherche Clinique 2005 P060228), Société Française de Rhumatologie.
Abstract (Originalsprache)
Objective
Recently, three distinct phenotypes of patients with Sjögren disease (SjD) have been described based on cluster analysis: B cell active with low symptoms (BALS), high systemic activity (HSA), and low systemic activity with high symptoms (LSAHS). We aimed to assess whether these clusters were associated with distinct biomarkers and the prognostic value of interferon (IFN) signature.
Methods
The Assessment of Systemic Signs and Evolution in Sjögren's Syndrome cohort is a 20‐year prospective cohort of patients with SjD. The following biomarkers were compared: IFN‐α2, IFN‐γ, CXCL10, CXCL13, BAFF, interleukin (IL)‐7, fms‐like tyrosine kinase 3 ligand, CCL19, and tumor necrosis factor receptor 2 (TNF‐RII). IFN signature was assessed using transcriptomic analysis. We then compared systemic and symptomatic evolution, and the risk of new immunosuppressant prescription and of lymphoma, according to the IFN signature across the three clusters.
Results
A total of 395 patients (94% female, median age 53 [interquartile range 43–63] years) were included. Higher levels of CXCL13, IL‐7, and TNF‐RII were found in the BALS and HSA clusters compared with the LSAHS cluster. A high IFN signature was mainly found in the BALS cluster (57%, vs 48% and 38% in the HSA and LSAHS clusters, respectively). This IFN signature was mainly driven by type I IFN, with higher levels of IFN‐α2. In the BALS cluster, a high IFN signature was associated with a higher risk of new immunosuppressant treatment (hazard ratio 9.38; 95% confidence interval 1.22–72.16). All lymphoma occurred in patients with high IFN signature.
Conclusion
The three SjD clusters displayed distinct expressions of IFN signature and markers of T and B cell activation, confirming distinct pathophysiologic mechanisms. High IFN signature could predict systemic evolution in the BALS cluster.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin-Bicêtre, Hôpital Beaujon, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Clichy, Centre de Recherche en Epid…
- Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin-Bicêtre, Hôpital Beaujon, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Clichy, Paris, France.
- Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
- Centre Hospitalier Universitaire de Montpellier and PhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, France.
- Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.
- General Hospital, Le Mans, France.
ORCID-Profile: Yann Nguyen, Maxime Beydon, Jacques-Eric Gottenberg, Jacques Morel, Divi Cornec, Valérie Devauchelle-Pensec, Carine Salliot, Gaëtane Nocturne
Förderung
- French Ministry of Health grant (Programme Hospitalier de Recherche Clinique 2005 P060228)
- Société Française de Rhumatologie
Zitieren
APA
Nguyen, Y., Beydon, M., Gottenberg, J. E., Morel, J., Perdriger, A., Dernis, E., Cornec, D., Devauchelle-Pensec, V., Sène, D., Dieudé, P., Couderc, M., Fauchais, A. L., Larroche, C., Vittecoq, O., Salliot, C., Hachulla, E., Le Guern, V., Mariette, X., Seror, R., & Nocturne, G. (2025). Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data. Arthritis & Rheumatology, 77(7), 876-883. https://doi.org/10.1002/art.43096
Vancouver
Nguyen Y, Beydon M, Gottenberg JE, Morel J, Perdriger A, Dernis E, et al. Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data. Arthritis & Rheumatology. 2025;77(7):876-883. doi:10.1002/art.43096
BibTeX
@article{Nguyen2025,
author = {Nguyen, Yann and Beydon, Maxime and Gottenberg, Jacques-Eric and Morel, Jacques and Perdriger, Aleth and Dernis, Emmanuelle and Cornec, Divi and Devauchelle-Pensec, Valérie and Sène, Damien and Dieudé, Philippe and Couderc, Marion and Fauchais, Anne-Laure and Larroche, Claire and Vittecoq, Olivier and Salliot, Carine and Hachulla, Eric and Le Guern, Véronique and Mariette, Xavier and Seror, Raphaèle and Nocturne, Gaëtane},
title = {Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data},
journal = {Arthritis & Rheumatology},
year = {2025},
volume = {77},
number = {7},
pages = {876--883},
doi = {10.1002/art.43096}
}
EUVIMED